ArticleScientific reports2024
Hybridisation of in silico and in vitro bioassays for studying the activation of Nrf2 by natural compounds.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Combating Antibacterial Resistance: The Integrative Role of Artificial Intelligence in Bio-Based Product Development.Antibiotics (Basel, Switzerland) · 2026Review
- Natural compounds attenuate combined chromium and arsenic-induced oxidative stress and nephritic apoptosis by activating the Nrf2/Keap1 signaling and associated xenobiotic metabolizing enzymes.Scientific reports · 2025Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
Oxidative stress, characterized by the damaging accumulation of free radicals, is associated with various diseases, including cardiovascular, neurodegenerative, and metabolic disorders. The transcription factor Nrf2 is pivotal in cellular defense against oxidative stress by regulating genes that detoxify free radicals, thus maintaining redox homeostasis and preventing cellular aging. Keap1 plays a regulatory role through its interaction with Nrf2, ensuring Nrf2 degradation under homeostatic conditions and facilitating its stabilization and nuclear translocation during oxidative stress. In the initial stage of our study, we conducted in vitro assays on HaCaT cells, a human keratinocyte cell line, to measure the expression levels of Nrf2 to reveal the activity of promising medicinal plants, which were then selected for further evaluation. Subsequently, this study leverages in silico techniques, integrating machine learning with molecular docking and dynamics, to screen natural compounds that potentially activate Nrf2. Data from the ChEMBL database were categorized into active and inactive compounds and used for training different machine-learning models to predict potential Nrf2 activators. The best-performing model was used to select compounds for further evaluation via molecular docking and dynamics, assessing their interactions with Keap1/Nrf2. The LC-MS/MS-based chemical profiles also validated the presence of these chemical compounds. This approach underscores the synergy between in vitro bioassays and in silico approaches in identifying Nrf2 activators, offering a cost-effective strategy for drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.